The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis

Huang, Ryan S; Mihalache, Andrew; Nafees, Abdulwadud; Hasan, Asad; Ye, Xiang Y; Liu, Zhihui; Leighl, Natasha B; Raman, Srinivas

doi:10.1093/jnci/djad268

Cited by 10 publications

(2 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, MTBs can improve overall survival by up to 11.2 months, and no cancer patient should be withheld from this benefit. 10 Our model is proof that calculated and coordinated interventions can improve cancer care, even with the slightest of resources.…”

mentioning

confidence: 58%

Mobilizing students to effect multidisciplinary cancer care: the Tumor Board Establishment Facilitation Forum

Abdul Rehman,

Jawwad,

Tahir

et al. 2024

The Lancet Regional Health - Southeast Asia

View full text Add to dashboard Cite

mentioning

confidence: 58%

Mobilizing students to effect multidisciplinary cancer care: the Tumor Board Establishment Facilitation Forum

Abdul Rehman,

Jawwad,

Tahir

et al. 2024

The Lancet Regional Health - Southeast Asia

View full text Add to dashboard Cite

“…Huang et al [ 10 ] conducted a meta-analysis report elucidating the influence of multidisciplinary cancer conferences on overall survival. The study revealed a median survival time of 30.2 months in the multidisciplinary cancer conference group, contrasting with 19 months in the control group [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Mucinous intestinal adenocarcinoma arising from mature cystic teratoma of the ovary treated with FOLFOX-6 - a case report

Bedoya-Ismodes,

Portugal,

Carmona-Lozano

et al. 2024

ecancer Journal

View full text Add to dashboard Cite

The malignant transformation of mature cystic teratomas during pregnancy is a rare occurrence in medical literature. In this case report, we present a remarkable instance of mucinous intestinal adenocarcinoma arising from a mature ovarian cystic teratoma diagnosed during pregnancy. This is among the few reports detailing the effective use of the FOLFOX 6 chemotherapy regimen for treating this type of intestinal cancer. Furthermore, we emphasize the immunohistochemical results that confirm the colorectal histological origin.

show abstract

Loss to Follow-Up in Patients With Proliferative Diabetic Retinopathy or Diabetic Macular Edema

Huang,

Naidu,

Mihalache

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceEffective management of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) requires reliable patient follow-up to prevent disease progression.ObjectiveTo investigate the sociodemographic and clinical factors associated with being lost to follow-up (LTFU) among individuals with PDR or DME treated with anti–vascular endothelial growth factor (VEGF) intravitreal injections (IVIs) or panretinal photocoagulation (PRP).Design, Setting, and ParticipantsThis cohort study included a multicenter, retrospective review of patients with PDR or DME treated in Toronto, Canada, from January 1, 2012, to December 31, 2021. Data were analyzed from February 1 to May 31, 2024.ExposuresAll patients received at least 1 anti-VEGF IVI or PRP session.Main Outcomes and MeasuresThe primary outcome was the LTFU rate, defined as the absence of an ophthalmic visit or intervention in the 1-year period following an individual’s last visit with the treating retinal specialist. Univariable and multivariable logistic regression models were conducted to evaluate associations between sociodemographic and clinical factors with the LTFU rate.ResultsOverall, 2961 patients with PDR or DME (mean [SD] age, 71 [13] years; 1640 [55.4%] male) were included, of whom 507 (17.1%) were LTFU over a mean (SD) follow-up period of 61 (22) months. In the multivariable analysis, older patients (age ≥85 years vs age &lt;65 years: odds ratio [OR], 0.58; 95% CI, 0.40-0.81; P = .002), those with worse baseline visual acuity (&gt;20/200 Snellen vs 20/40 Snellen or better: OR, 0.68; 95% CI, 0.48-0.97; P = .04), those with DME (OR vs no DME, 0.60; 95% CI, 0.43-0.83; P = .003), those with frequent clinic visits (≥6 visits vs &lt;6 visits: OR, 0.78; 95% CI, 0.62-0.98; P = .04), and those with a high anti-VEGF IVI burden in the first year (OR vs low anti-VEGF burden, 0.40; 95% CI, 0.21-0.76; P = .006) were less likely to be LTFU. In contrast, males (OR vs females, 1.23; 95% CI, 1.04-1.52; P = .04), patients living further from the point of care (&gt;200 vs ≤20 km OR, 2.65; 95% CI, 1.85-3.76; P &lt; .001), and those treated with PRP (OR vs anti-VEGF IVIs, 2.10; 95% CI, 1.24-3.55; P &lt; .001) were more likely to be LTFU. Compared with White patients, Black patients (OR, 2.10; 95% CI, 1.50-2.95; P &lt; .001) and Hispanic patients (OR, 1.54; 95% CI, 1.05-2.21; P = .03) were more likely to be LTFU.Conclusions and RelevanceThis cohort study found multiple factors associated with LTFU rates. Identifying individuals at higher risk of LTFU and developing targeted strategies may reduce disease progression and vision loss in individuals with PDR.

show abstract

The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis

Cited by 10 publications

References 82 publications

Mobilizing students to effect multidisciplinary cancer care: the Tumor Board Establishment Facilitation Forum

Mobilizing students to effect multidisciplinary cancer care: the Tumor Board Establishment Facilitation Forum

Mucinous intestinal adenocarcinoma arising from mature cystic teratoma of the ovary treated with FOLFOX-6 - a case report

Loss to Follow-Up in Patients With Proliferative Diabetic Retinopathy or Diabetic Macular Edema

Contact Info

Product

Resources

About